| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.tejnaksh.com | |
| Market Cap | 125.94 Cr. | |
| Enterprise Value(EV) | 125.92 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.58 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 48.03 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 46.72 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 21.21 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 5.85 | Calculated using Price: 124.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.02 Cr. | 10,156,800 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is an integrated healthcare delivery service provider, committed to delivering quality healthcare services to its patients in modern facilities. Its operations are divided across four key vertical streams in healthcare delivery, namely - “Pediatric Urologyâ€, “Adult Urology (Male, Female)â€, “Andrology and Sexual Dysfunction†and “Nephrology, Dialysis and Renal Transplantâ€. It offers a gamut of more than 65 healthcare services under these streams. A base of over 65 employees and consultants supports its healthcare facility network. The company's healthcare facilities use advanced technology and its doctors, nurses and other healthcare professionals follow treatment protocols that match international standards. A majority of its healthcare facilities provide secondary, tertiary and quaternary healthcare services to patients. Some of its healthcare facilities provide super speciality quaternary healthcare to patients in key specialty areas such as Pediatric Urology and Adult Urology (Male, Female). | ||
| 1 Day |
|
+5.74% |
| 1 Week |
|
-6.74% |
| 1 Month |
|
+17.49% |
| 3 Month |
|
+7.83% |
| 6 Month |
|
-10.89% |
| 1 Year |
|
-13.16% |
| 2 Year |
|
+142.65% |
| 5 Year |
|
+47.19% |
| 10 Year |
|
| 7 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 21.17 | 26.68 | 34.98 | 26.93 | 15.10 | 12.71 | 15.05 | |
| Return on Capital Employed (%) | 34.00 | 29.35 | 32.66 | 27.59 | 17.78 | 14.20 | 17.20 | |
| Return on Assets (%) | 19.32 | 16.96 | 17.97 | 14.93 | 9.10 | 8.36 | 10.38 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 6 | 8 | 10 | 13 | 15 | 17 | 20 | 21 | |
| Non Curr. Liab. | 0 | 7 | 6 | 6 | 7 | 5 | 7 | 7 | |
| Curr. Liab. | 0 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | |
| Minority Int. | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||
| Equity & Liab. | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 | |
| Non Curr. Assets | 6 | 14 | 17 | 18 | 18 | 21 | 25 | 25 | |
| Curr. Assets | 1 | 2 | 3 | 5 | 7 | 3 | 5 | 6 | |
| Misc. Exp. not W/O | |||||||||
| Total Assets | 7 | 16 | 20 | 22 | 25 | 25 | 30 | 31 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 5 | 7 | 14 | 20 | 17 | 12 | 13 | 12 | |
| Other Income | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | |
| Total Income | 5 | 7 | 15 | 21 | 17 | 12 | 13 | 13 | |
| Total Expenditure | -2 | -4 | -9 | -16 | -13 | -8 | -8 | -8 | |
| PBIDT | 2 | 3 | 6 | 6 | 4 | 4 | 5 | 5 | |
| Interest | 0 | -1 | -1 | -1 | -1 | 0 | -1 | ||
| Depreciation | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Exceptional Items | |||||||||
| PAT | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Share Associate | 0 | ||||||||
| Other Related Items | |||||||||
| Consolidated Net Profit | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 | |
| Adjusted EPS | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | 2 | 4 | 3 | 1 | 1 | 9 | |
| Cash Fr. Inv. | -3 | -8 | -3 | -2 | -1 | 2 | -11 | |
| Cash Fr. Finan. | 0 | 6 | -1 | -2 | 0 | -3 | 2 | |
| Net Change | 0 | 1 | 1 | -1 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 1 | 2 | 1 | 1 | 1 | 1 |
|
Mon, 30 Jan 2023
Board Meeting Intimation for Agenda Mentioned In Notice Enclosed Herewith. Tejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2023 inter alia to consider and approve a. Un-audited financial result (Standalone and Consolidated) for quarter ended on December 31 2022;b. Sub-division of (Change in face value) of equity share of the Company; c. The Appointment of Mr. Nandish Dave Company Secretary as a Secretarial Auditor of the Company for FY 2022-23;d. Any other matter with the permission of the Chair. |
|
Mon, 23 Jan 2023
Announcement Under Regulation 30 Announcement under Regulation 30 and Show Telecasted on Sony Liv -Shark Tank Season-2 of a Product Name P-Flow. |
|
Sun, 15 Jan 2023
Announcement Under Regulation 30 W.R.T. Investor Meet At Shark Tank (Popular TV Show) With reference to the subject cited above; we are pleased to inform you that Our Managing Director Dr. Ashish Rawandale and Director Dr. Preeti Rawandale presented our product Pflow in the tank. Thiswas done before the renowned Investors at Shark Tank which is popular Sony TV show.They showcased our product named P-FLOW which helps diagnose prostate and urine infection athome.This is to inform you that the show maybe telecasted on Sony Liv Entertainment Channel. |
| Mon, 30 Jan 2023 |
Opening at High
|
High Increase in 1 Month
|
High Increase in 2 Years
|
Closing Near 100 SMA
|
Close Crossing 100 SMA From Above
|
Equities
M.F.
Sectors